REG - Genedrive PLC - Board Changes

GenedriveAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260526:nRSZ5629Fa&default-theme=true

RNS Number : 5629F  Genedrive PLC  26 May 2026

26 May 2026

genedrive plc

("genedrive" or the "Company")

 

Board changes

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
today announces that Mr David Nugent has joined the Board as a Non-Executive
Director with immediate effect. David has been a shareholder in the Company
for several years and more recently was a key cornerstone investor in the
successful equity financing announced on 13 February 2026. He owns over 25% of
the Company's issued share capital and is the Company's largest shareholder.
David has volunteered not to be paid a fee for acting as a Non-Executive
Director until the Company becomes EBITDA positive.

 

Further, Dr. Ian Gilham, who has been a Director of the Company since 2014,
including acting as Chairman since 2015, has informed the Board that he
anticipates stepping down as Chairman and a Director of genedrive by the end
of June 2026. In addition, Chris Yates, who has been a Non-Executive Director
of the Company since 2018 has informed the Board that he intends to step down
as a Director to focus on his other professional commitments.  Chris has
agreed to assist the Board during the process to appoint new Non-Executive
Board members prior to stepping down sometime over the coming weeks.

 

The Board is commencing the process to recruit a new independent Non-Executive
Chairman as well as two other independent Non-Executive Directors and further
announcements will be made in due course.

 

Dr. Ian Gilham, Chairman of genedrive plc, said: "On behalf of my fellow
Directors I am pleased to welcome David onto the Board today. His support for
the Company has been critical to funding our continued growth strategy and we
look forward to working closely with him as we execute against our plans to
increase the sales and adoption of our two pharmacogenetic tests. Having
served as Director of the Company since 2014 it is appropriate that we start
the process to find a new Non-Executive Chairman and the Company will update
shareholders on this process in due course."

 

David Nugent, Non-Executive Director of genedrive plc, said on his
appointment: "I would like to thank Ian and Chris for their commitment to
genedrive and recognise their significant contribution over many years. I look
forward to continuing to work with them as we appoint a Chair and two
independent Non-Executive Directors.

 

"genedrive is in its strongest position for many years, with two point-of-care
pharmacogenetic tests now on the market which offer highly promising
commercial opportunities. I am excited to be joining the Board and working
with Gino and Russ as the Company drives adoption and executes its commercial
strategy in the UK and internationally."

 

Additional Information on the Board Appointment

 

The following additional information is provided with regards to the
appointment of David Grant Nugent, aged 57, in accordance with Rule 17 and
Schedule 2(g) of the AIM Rules for Companies:

 

 

 Current directorships/partnerships:  Former directorships/partnerships (within the last five years):
 Newspoint Limited                    None
 Nugent (SW) Limited
 Primeco Limited
 Robonet Limited
 Roboweb Limited

 

David Nugent was a director of Howard Nugent Limited which was wound up under
the provisions of the Insolvency Act 1986 in March 2011.

 

David Nugent and his connected parties hold 401,500,000 ordinary shares in the
Company as detailed in the TR1 announcement issued on 6 May 2026.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of
the AIM Rules for Companies.

 

 

 genedrive plc
                                                        +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO
                                                        https://investors.genedrive.com/s/e0025c
                                                        (https://investors.genedrive.com/s/e0025c)

 Peel Hunt LLP (Nominated Adviser and Broker)
                                                        +44 (0)20 7418 8900
 James Steel

 5654 & Company  (Media & Investor Relations)           genedrive@5654.co.uk
 Matthew Neal                                           +44 (0)7917 800 011
 Melissa Gardiner                                       +44 (0)7757 697357

 

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
(https://investors.genedrive.com/s/efea03)

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) ).

 

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company
focused on rapid, point-of-care diagnostic tests to guide safe and effective
drug prescription in emergency and acute care settings.

 

genedrive's proprietary technology platform enables clinicians to prescribe
safer and more effective therapies based on a patient's genetic profile,
supporting improved outcomes while reducing pressure on healthcare systems,
lowering downstream healthcare costs through the prevention of avoidable
complications and earlier, more effective intervention

 

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical
use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not
respond to the current standard of care, Clopidogrel, used to reduce risk of
secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent
antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment
decisions within actionable timeframes at the point of care.

 

Headquartered in Manchester, genedrive is focused on scaling UK-developed
precision diagnostics within routine care and leveraging real-world evidence
to support broader international adoption and commercial growth.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMZGZKVKNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved